ADZYNMA (Takeda Pharmaceutical: ADAMTS13, recombinant-krhn) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! ...
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
and cost-effective biologic therapies, and leveraging advancements in genetic screening. Growth is driven by rising autoimmune disorders, strategic partnerships, and regional manufacturing initiatives. Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "ADZYNMA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ADZYNMA market has witnessed significant growth, driven by limited treatment availability for congenital thrombotic thrombocytopenic purpura (cTTP) and high mortality rates in untreated patients. The reliance on plasma exchange therapy, advancements in genetic disorder diagnosis, and unmet needs in rare disease care have further propelled growth. In the future, an increase in rare disease awareness programs, improved affordability of targeted therapies, expansion of specialty treatment centers, and rising genetic screening adoption are expected to fuel the market's expansion. Major trends
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an "overweight" rating on the stock.MarketBeat
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 3/24/26 - Form 144
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- PTGX's page on the SEC website